Northwestern University: Carcinoma, Hepatocellular trials

The registry lists 10 Carcinoma, Hepatocellular studies with Northwestern University as lead sponsor. 2 are open to participants now and 3 have results posted.

Early Phase 1 1Phase 1 3Phase 2 4No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Defining the Ablative Dose for Y-90 TARERecruitingNCT07586046Phase 2
• Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-riskRecruitingNCT05620771Phase 2
• Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD StudyActive, not recruitingNCT04550481Phase 2Results posted
• Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver CancerCompletedNCT02837029Phase 1Results posted
• A2ALL-Patients Safety System Improvements in Living Donor Liver TransplantationCompletedNCT02073435Results posted
• Optimizing Y90 Therapy for Radiation LobectomyActive, not recruitingNCT04390724
• Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical ResectionTerminatedNCT03812562Early Phase 1
• Biomarker Analyses in Hepatocellular Carcinoma (HCC) Patients Treated With TheraSphere®TerminatedNCT03203837
• Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular CarcinomaCompletedNCT00846131Phase 1
• Epirubicin and Celecoxib in Treating Patients With Hepatocellular CarcinomaCompletedNCT00057980Phase 1/2